A recent study confirmed amoxicillin’s lower risk of treatment failure compared to penicillin V in treating pediatric pneumonia, with no difference in severe complications.
Is there room for MASH drugs in a GLP-1 world?
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS